Phase I and pharmacokinetic study of AI-850, a novel microparticle hydrophobic drug delivery system for paclitaxel

Clinical Cancer Research

Volumn 13, Issue 11, 2007, Pages 3293-3301

  Mita, Alain C ^a   Olszanski, Anthony J ^b   Walovitch, Richard C ^c   Perez, Raymond P ^b   MacKay, Kathleen ^b   Tuck, David P ^d   Simmons, Cecilia ^a   Hammond, Susan ^b   Mita, Monica M ^a   Beeram, Muralidhar ^a   Stone, Anne J ^c   Rowinsky, Eric K ^a   Lewis, Lionel D ^b,e  

^a CTRC Institute for Drug Development   (United States)

^b NORRIS COTTON CANCER CENTER   (United States)

^c Acusphere Inc   (United States)

^d YALE CANCER CENTER   (United States)

^e DARTMOUTH HITCHCOCK MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AI 850; PACLITAXEL; UNCLASSIFIED DRUG;

ADULT; AGED; ALOPECIA; ANEMIA; ANOREXIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; BACKACHE; CLINICAL ASSESSMENT; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG BLOOD LEVEL; DRUG DELIVERY SYSTEM; DRUG DOSE ESCALATION; DRUG FORMULATION; DRUG INFUSION; DRUG SAFETY; DYSPNEA; EDEMA; FATIGUE; FEASIBILITY STUDY; FEMALE; FEVER; FLUSHING; HUMAN; HYDROPHOBICITY; INJECTION SITE REACTION; LABORATORY TEST; LIQUID CHROMATOGRAPHY; MALE; MASS SPECTROMETRY; MULTIPLE CYCLE TREATMENT; MYALGIA; NAUSEA AND VOMITING; NEUROPATHY; NEUTROPENIA; NON HEMATOLOGIC TOXICITY; PARESTHESIA; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RASH; SENSORY NEUROPATHY; SIDE EFFECT; SKIN TINGLING; TENDON REFLEX; THORAX PAIN; THROMBOCYTOPENIA;

ADULT; AGED; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CAPSULES; CHROMATOGRAPHY, LIQUID; DRUG DELIVERY SYSTEMS; FEMALE; HUMANS; HYDROPHOBICITY; MALE; MASS SPECTROMETRY; MAXIMUM TOLERATED DOSE; MIDDLE AGED; NEOPLASMS; PACLITAXEL; TREATMENT OUTCOME;

EID: 34250612627     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-06-2496     Document Type: Article

References (46)

1. Wani MC, Taylor HL, Wall ME, Coggon P, McPhail AT. Plant antitumor agents. VI. The isolation and structure of taxol, a novel antileukemic and antitumor agent from Taxus brevifolia. J Am Chem Soc 1971;93:2325-7.
2. Rowinsky EK, Donehower RC. Paclitaxel (Taxol). N Engl J Med 1995;332:1004-14.
3. Rowinsky EK, Tolcher AW. Antimicrotubule agents. In: DeVita V, Hellman S, Rosenberg SA, editors. Cancer: principle and practice of oncology. Philadelphia (PA): Lippincott Williams and Wilkins; 2001. p. 431-51.
4. Crown J, O'Leary M. The taxanes: an update. Lancet 2000;355:1176-8.
5. Schiff PB, Fant J, Horwitz SB. Promotion of microtubules assembly in vitro by taxol. Nature 1979;277:665-7.
6. Straubinger RM. Biophamaceutics of paclitaxel (Taxol): formulation, activity and pharmacokinetics. In: Suffness M, editor. Taxol®: science and applications. Boca Raton (FL): CRC Press; 1996. p. 237-58.
7. Liggins RT, Hunger WL, Burt HM. Solid-state characterization of paclitaxel. J Pharm Sci 1997;86:1458-63.
8. Rowinsky EK. The taxanes: dosing and scheduling considerations. Oncology 1997;11:7-19.
9. Greco FA, Hainsworth TM. One-hour paclitaxel infusions: a review of safety and efficacy. Cancer J Sci Am 1999;5:179-91.
10. Adams JD, Flora KP, Goldspiel BR, Wilson JW, Arbuck SG, Finley R. Taxol: a history of pharmaceutical development and current pharmaceutical concerns. J Natl Cancer Inst Monogr 1993;15:141-7.
11. Acusphere, Inc. AI-850 Investigator's Brochure. Watertown (MA): Acusphere, Inc.; 2001.
12. Straub JA, Chickering DE, Lovely JC, et al. Intravenous hydrophobic drug delivery: a porous particle formulation of paclitaxel (AI-850). Pharm Res 2005;22:347-55.
13. Alexander MS, Kiser MM, Culley T, et al. Measurement of paclitaxel in biological matrices: highthroughput liquid chromatographic-tandem mass spectrometric quantification of paclitaxel and metabolites in human and dog plasma. J Chromatogr 2002;785:253-61.
14. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000;92:205-16.
15. Dorr RT. Pharmacology and toxicology of Cremophor EL diluent. Ann Pharmacother 1994;28:S11-4.
16. Van Zuylen L, Verweij J, Sparrenboom A. Role of formulation vehicles in taxane pharmacology. Invest New Drugs 2001;19:125-41.
17. Ten Tije AJ, Verveij J, Loos WJ, Sparrenboom A. Pharmacological effects of formulation vehicles. Clin Pharmacokinet 2002;42:665-85.
18. Weiss RB, Donehower RC, Wiernik PH. Hypersensitivity reactions from Taxol. J Clin Oncol 1990;8:1263-8.
19. Dye D, Watkins J. Suspected anaphylactic reaction to Cremophor EL. Br Med J 1980;280:1353.
20. Volcheck GW, Van Dellen RG. Anaphylaxis to intravenous cyclosporine and tolerance to oral cyclosporine: case report and review. Ann Allergy Asthma Immunol 1998;80:159-63.
21. Szebeni J, Muggia FM, Alving CR. Complement activation by Cremophor EL as a possible contributor to hypersensitivity to paclitaxel: an in vitro study. J Natl Cancer Inst 1998;90:300-6.
22. Van Zuylen L, Gianni L, Verveij J, et al. Inter-relationships of paclitaxel disposition, infusion duration and cremophor EL kinetics in cancer patients. Anticancer Drugs 2000;11:331-7.
23. Windebank AJ, Blexrud MD, de Groen PC. Potential neurotoxicity of the solvent vehicle for cyclosporine. J Pharmacol Exp Ther 1994;268:1051-6.
24. Boer HH, Moorer-van Delft CM, Muller LJ, Kiburg B, Vermoken JB, Heimans JJ. Ultrastructural neuropathologic effects of Taxol on neurons of the freshwater snail Lymnaea stagnalis. J Neurooncol 1995;25:49-57.
25. Brat DJ, Windebank AJ, Brimijoin S. Emulsifier for intravenous cyclosporine inhibits neurite outgrowth, causes deficit in rapid axonal transport and leads to structural abnormalities in differentiating N1E.115 neuroblastoma. J Pharmacol Exp Ther 1992;261:803-10.
26. Sparrenboom A, Van Zuyien l, Brouwer E, et al. Cremophor EL-mediated alteration of paclitaxel distribution in human blood: clinical pharmacokinetic implications. Cancer Res 1999;59:1454-7.
27. van Tellingen O, Huizing MT, Panday VR, Schellens JH, Nooijen WJ, Beijnen JH. Cremophor EL causes (pseudo-) non-linear pharmacokinetics of paclitaxel in patients. Br J Cancer 1999;81:330-5.
28. Gelderblom H, Mross K, ten Tije AJ, et al. Comparative pharmacokinetics of unbound paclitaxel during 1-and 3-hour infusions. JClin Oncol 2002;20:574-81.
29. Knemeyer I, Wientjes MG, Au JL. Cremophor reduces paclitaxel penetration into bladder wall during intravesical treatment. Cancer Chemother Pharmacol 1999;44:241-8.
30. Woodcock DM, Jefferson S, Linsenmeyer ME, et al. Reversal of the multidrug resistance phenotype with cremophor EL, a common vehicle for water-insoluble vitamins and drugs. Cancer Res 1990;50:4199-203.
31. Sparrenboom A, Verveij J, vander Burg MEL, et al. Disposition of Cremophor EL in humans limits the potential for modulation of the multidrug resistance phenotype in vivo. Clin Cancer Res 1998;4:1937-42.
32. Ibrahim NK, Desai N, Legha S, et al. Phase I and pharmacokinetic study of ABI-007, a Cremophor-free, protein-stabilized, nanoparticle formulation of paclitaxel. Clin Cancer Res 2002;8:1038-44.
33. Kim TY, Kim DW, Chung JY, Shin SG, Kim SC, Heo DS. Phase I and pharmacokinetic study of Genexol-PM, a cremophor-free, polymeric micelle-formulated paclitaxel, in patients with advanced malignancies. Clin Cancer Res 2004;10:3708-16.
34. Soepenberg O, Sparreboom A, de Jonge MJ, et al. Real-time pharmacokinetics guiding clinical decisions; phase I study of a weekly schedule of liposome encapsulated paclitaxel in patients with solid tumours. Eur J Cancer 2004;40:681-8.
35. Lundberg BB. A submicron lipid emulsion coated with amphipathic polyethylene glycol for parenteral administration of paclitaxel (Taxol). J Pharm Pharmacol 1997;49:16-21.
36. Nicolaou KC, Riemer C, Kerr MA, Rideout D, Wrasidlo W. Design, synthesis and biological activity of protaxols. Nature 1993;364:464-6.
37. Paradis R, Page M. New active paclitaxel amino acids derivatives with improved water solubility. Anticancer Res 1998;18:2711-6.
38. O'Shaughnessy J, Tjulandin S, Davidson N, et al. ABI-007 (Abraxane™), a nanoparticle albumin-bound paclitaxel demonstrates superior efficacy vs Taxol in MBC: a phase III trial [abstract #44]. Proc SABCS 2005.
39. Gradishar WJ, Tjulandrin S, Davidson N, et al. Superior efficacy of albumin-bound paclitaxel, ABI-007, compared to polyethylated castor-oil-based paclitaxel in women with metastatic breast cancer: results of a phase III trial. J Clin Oncol 2005;23:7794-803.
40. Johnson MD, Drew RH, Perfect JR. Chest discomfort associated with liposomal amphotericin B: report of three cases and review of the literature. Pharmacotherapy 1998;18:1053-61.
41. Szebeni J. Complement activation-related pseudoallergy caused by amphiphilic drug carriers: the role of lipoproteins. Curr Drug Deliv 2005;4:443-9.
42. Szebeni J. Complement activation-related pseudoallergy: a new class of drug-induced acute immune toxicity. Toxicology 2005;216:106-21.
43. Essayan DM, Kagey-Sobotka A, Colarusso PJ, Lichtenstein LM, Ozols RF, King ED. Successful parenteral desensitization to paclitaxel. J Allergy Clin Immunol 1996;97:42-6.
44. Ohtsu T, Sasaki Y, Tamura T, et al. Clinical pharmacokinetics and pharmacodynamics of paclitaxel: a 3-hour infusion versus a 24-hour infusion. Clin Cancer Res 1995;1:599-606.
45. Kearns C, Gianni L, Egorin MJ. Paclitaxel pharmacokinetics and pharmacodynamics. Semin Oncol 1995;22:16-23.
46. Van Zuylen L, Karlsson MO, Verweij J, et al. Pharmacokinetic modeling of paclitaxel encapsulation in Cremophor EL micelles. Cancer Chemother Pharmacol 2001;47:309-18.